<DOC>
	<DOC>NCT02104843</DOC>
	<brief_summary>The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.</brief_summary>
	<brief_title>Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin</brief_title>
	<detailed_description>IND Number: 79,599/101,943 Primary Purpose: Other - Phase 1 Clinical Pharmacology drug interaction study in healthy subjects</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy subjects with no clinically significant deviations from normal in medical history, physical exam findings, 12 lead ECG measurements and clinical laboratory tests Females must be of nonchildbearing potential Women of childbearing potential Any significant acute or chronic medical condition Inability to tolerate oral medications Inability to be venipunctured and/or tolerate venous access Abnormal liver function tests Current or recent (within 3 months of dosing) gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>